Gastric Antisecretory Drug Market Trends, Business Overview, Industry Growth and Forecast to 2023-2029
Gastric antisecretory drug market is anticipated to grow at a CAGR of 3.8% during the forecast period. Antisecretory drugs assist in reducing the normal rate of secretion of a body fluid that reduces acid secretion into the stomach. Such drugs include antimuscarinic drugs, H2-receptor antagonists and proton-pump inhibitors. The surging prevalence of gastrointestinal disorders such as dyspepsia, peptic ulcer, and gastroesophageal reflux is the prominent factor that has boosted the demand for gastric antisecretory drugs. In the US, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time, according to Harvard Health. Apart from these, the growing prevalence of stress-induced ulcers due to changing lifestyles and diet, increasing smoking rate, and progressive population of geriatrics is anticipated to promote the growth of the global gastric antisecretory drug market. Moreover, significant partnerships, collaborations and new product development by the market players are likely to generate new growth opportunities for the market.
To Request a Sample of our Report on Gastric Antisecretory Drug Market https://www.omrglobal.com/request-sample/gastric-antisecretory-drug-market
For instance, in July 2021, Shandong Luoxin Pharmaceutical Group Stock Co., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. signed a cooperation agreement with South Korea-based HK Inno. N Corp. for the development, manufacture, and commercialization of Tegoprazan injections in China. Tegoprazan injections have mainly been developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and upper gastrointestinal bleeding as well as for the prevention of stress gastric mucosa injury. Similar, in July 2020, Cadila Pharmaceuticals Ltd. launched Esomeprazole tablets for the treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc. Esomeprazole which is a proton pump inhibitor (PPI), acts on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion. Esomeprazole provides higher rates of healing of erosive GERD and sustained resolution of heartburn in patients.
A full Report of Gastric Antisecretory Drug Market https://www.omrglobal.com/industry-reports/gastric-antisecretory-drug-market
Key Company Analysis
Overview
Financial Analysis
Analysis
Recent Developments
Key Strategy Analysis
Market Segmentation
Global Gastric Antisecretory Drug Market by Type
H2-receptor Antagonists
Gastric Proton Pump Inhibitors
Global Gastric Antisecretory Drug Market by Application
Peptic Ulcer
Gastroesophageal Reflux
Global Gastric Antisecretory Drug Market by End-User
Hospital
Clinic
For More Customized Data, Request for Report Customization https://www.omrglobal.com/report-customization/gastric-antisecretory-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com
Contact no: +91 780-304-0404